AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
This study is conducted to assess the safety, tolerability and preliminary efficacy of AST2818 in patients with advanced Non Small Cell Lung Cancer (NSCLC).
Advanced NSCLC
DRUG: Alflutinib
Objective response rate of Alflutinib, Evaluation of objective response rate assessed by RECIST 1.1, CT or MRI at screening and every 2 Cycles (from first dose of multiple dosing) until disease progression or withdrawal from study, whichever came first, assessed up to 52 weeks.
Duration of response of Alflutinib, Duration of response assessed by RECIST 1.1, CT or MRI at screening and every 2 Cycles (from first dose of multiple dosing) until disease progression or withdrawal from study, whichever came first, assessed up to 52 weeks.|Progression free survival of Alflutinib, Progression of tumor was assessed by RECIST 1.1 thereby to evaluate progression free survival, CT or MRI at screening and every 2 Cycles (from first dose of multiple dosing) until disease progression or withdrawal from study, whichever came first, assessed up to 52 weeks.|Clinical benefit rate of Alflutinib, Clinical benefit rate was calculated by adding up complete remission, partial remission and stabilization of disease assessed by RECIST 1.1, CT or MRI at screening and every 2 Cycles (from first dose of multiple dosing) until disease progression or withdrawal from study, whichever came first, assessed up to 52 weeks.|Disease control rate of Alflutinib, Progression of tumor was assessed by RECIST 1.1 thereby to evaluate disease control rate, CT or MRI at screening and every 2 Cycles (from first dose of multiple dosing) until disease progression or withdrawal from study, whichever came first, assessed up to 52 weeks.|Incidence and Severity of Treatment-Emergent Adverse Events, Assessed by number and severity of adverse events as recorded on the case report form, vital signs, laboratory variables, physical examination, electrocardiogram, ophthalmic examinations, RECIST1.1, and NCI CTCAE v4.03, Adverse events will be collected from baseline until 28 days after the last dose|Steady state Maximum Plasma Concentration [Cmax] of multiple doses Alflutinib and 2 metabolites, Cmax of Alflutinib and 2 metabolites at steady state following multiple doses, Blood samples will be collected from each subject at pre-specified times during the multiple dosing cycles (Cycle 1-pre-dose Day 1, 8, 15. Cycle 2 D1- pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 hours post dose)|Steady state peak plasma time [tmax] of multiple doses Alflutinib and 2 metabolites, tmax of Alflutinib and 2 metabolites at steady state following multiple doses., Blood samples will be collected from each subject at pre-specified times during the multiple dosing cycles (Cycle 1-pre-dose Day 1, 8, 15. Cycle 2 D1- pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 hours post dose)|Steady state Cmin (Minimum Plasma Concentration) of multiple doses Alflutinib and 2 metabolites, Cmin of Alflutinib and 2 metabolites at steady state following multiple doses., Blood samples will be collected from each subject at pre-specified times during the multiple dosing cycles (Cycle 1-pre-dose Day 1, 8, 15. Cycle 2 D1- pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 hours post dose)|Steady state area under the plasma concentration versus time curve [AUC] of multiple doses Alflutinib and 2 metabolites, AUC of Alflutinib and 2 metabolites at steady state following multiple doses., Blood samples will be collected from each subject at pre-specified times during the multiple dosing cycles (Cycle 1-pre-dose Day 1, 8, 15. Cycle 2 D1- pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 hours post dose)|Steady state clearance of multiple doses Alflutinib and 2 metabolites, Clearance of Alflutinib and 2 metabolites at steady state following multiple doses., Blood samples will be collected from each subject at pre-specified times during the multiple dosing cycles (Cycle 1-pre-dose Day 1, 8, 15. Cycle 2 D1- pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 hours post dose)|Accumulation ratio of multiple doses Alflutinib and 2 metabolites, Accumulation ratio of Alflutinib and 2 metabolites following multiple doses., Blood samples will be collected from each subject at pre-specified times during the multiple dosing cycles (Cycle 1-pre-dose Day 1, 8, 15. Cycle 2 D1- pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 hours post dose)
This study is conducted to assess the safety, tolerability and preliminary efficacy of AST2818 in patients with advanced Non Small Cell Lung Cancer (NSCLC).